Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given "Buy" Rating at D. Boral Capital

Key Points

• D. Boral Capital has reiterated a buy rating for Lineage Cell Therapeutics and set a price target of $2.00, indicating a potential upside of 60% from its last close.
• HC Wainwright also maintains a buy rating with a target price of $9.00, contributing to a consensus price target of $4.25 among analysts.
• Lineage Cell Therapeutics' shares have risen 6.8%, opening at $1.25, with the company demonstrating strong institutional interest as 62.47% of its stock is held by institutional investors.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $2.00 target price on the stock. D. Boral Capital's price objective indicates a potential upside of 70.94% from the stock's previous close.

Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Monday, June 23rd. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Lineage Cell Therapeutics presently has a consensus rating of "Buy" and an average target price of $4.25.

Lineage Cell Therapeutics Trading Down 3.3%

NYSEAMERICAN LCTX traded down $0.04 on Wednesday, hitting $1.17. 988,800 shares of the company were exchanged, compared to its average volume of 1,481,965. The firm has a 50 day moving average of $1.05 and a two-hundred day moving average of $0.73. The company has a market cap of $267.18 million, a P/E ratio of -6.50 and a beta of 1.66. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $1.31.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Two Sigma Advisers LP lifted its position in Lineage Cell Therapeutics by 312.2% during the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock valued at $44,000 after purchasing an additional 65,864 shares during the period. Two Sigma Investments LP acquired a new position in Lineage Cell Therapeutics during the 4th quarter valued at about $152,000. Barclays PLC lifted its position in Lineage Cell Therapeutics by 10.8% during the 4th quarter. Barclays PLC now owns 234,069 shares of the company's stock valued at $118,000 after purchasing an additional 22,769 shares during the period. Comerica Bank lifted its position in Lineage Cell Therapeutics by 220.0% during the 4th quarter. Comerica Bank now owns 800,000 shares of the company's stock valued at $402,000 after purchasing an additional 550,000 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Lineage Cell Therapeutics by 1,058.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company's stock valued at $1,147,000 after purchasing an additional 2,085,972 shares during the period. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.